SCHEMBL4895247

SCHEMBL4895247

CN(C)C(=O)c1ccc(Cl)nc1Nc1ccccn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 6/20 0.43
▸ GAA P10253 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ PKM P14618 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ MAPK10 P53779 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.39
▸ CCNA2 P20248 1/20 0.39
▸ CDK2 P24941 1/20 0.39
▸ CCNA1 P78396 1/20 0.39
▸ CDK5 Q00535 1/20 0.39
▸ DYRK1A Q13627 1/20 0.39
▸ CDK5R1 Q15078 1/20 0.39
▸ SMARCA2 P51531 1/20 0.39
▸ SMARCA4 P51532 1/20 0.39
▸ TSHR P16473 1/20 0.38
▸ ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4899171 0.85 SYK (0.43) SMN1; SMN2NPC1PKMRAB9AMAPK10
SCHEMBL4899989 0.83 KDM4E (0.44) GRM5GAASMN1; SMN2NPC1PKM
SCHEMBL8828641 0.70 CNR1 (0.43) SMN1; SMN2NPC1RAB9AALDH1A1MEN1
SCHEMBL18838559 0.69 ALDH1A1 (0.42) SMN1; SMN2NPC1RAB9AALDH1A1CDK2
SCHEMBL4892092 0.69 MAPT (0.55) GAASMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL3138350 0.68 GRM5 (0.55) GRM5GAASMN1; SMN2NPC1PKM
SCHEMBL4892317 0.68 MECP2 (0.43) GRM5GAASMN1; SMN2NPC1RAB9A
SCHEMBL17398031 0.67 KDM4E (0.44) GAASMN1; SMN2NPC1PKMRAB9A
SCHEMBL9599045 0.66 NPC1 (0.63) GRM5GAASMN1; SMN2NPC1PKM
SCHEMBL2201670 0.66 SMN1; SMN2 (0.61) SMN1; SMN2NPC1LMNARXFP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080108600-A1 Polycyclic Pyridines as Potassium Ion Channel Modulators ICAGEN, INC. (US) 2008-05-08 — — US disclosed
EP-1737852-A2 POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS Icagen, Inc. (US) 2007-01-03 — — EP disclosed
WO-2005100349-A2 POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS ICAGEN, INC. (US) 2005-10-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108600-A1 Polycyclic Pyridines as Potassium Ion Channel Modulators KCNJ2, KCNH2, KCNQ1 GRM5 392/4885GAA 4613/4885SMN1; SMN2 3670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback